We previously reported that the inflammasome inhibitor cucurbitacin D (CuD) induces apoptosis in human leukemia cell lines. In the present study, we investigated the effects of co-treatment with an additional Bcl-xL inhibitor, Z36. Treatment with Z36 induced cell death in leukemia cell lines, with MT-4 cells exhibiting the lowest sensitivity to Z36. Co-treatment of cells with Z36 and CuD resulted in a greater degree of cell death for Hut78 and Jurkat cells than treatment with CuD alone. In contrast, co-treatment of MT-4 cells with Z36 and CuD had a suppressive effect on cell death. The autophagy inhibitor 3-methyladenine (3-MA) suppressed the growth of leukemia cell lines HuT78, Jurkat, MT-1, and MT-4. CuD-induced cell death was enhanced by 3-MA in Jurkat cells, but inhibited in MT-4 cells. Western blotting results revealed cleavage of poly(ADP ribose) polymerase (PARP), supporting CuD-induced cell death; 3-MA enhanced CuDZ36-induced PARP cleavage. Taken together, our results indicate that autophagy negatively regulates chemical-induced cell death of leukemia cells, and that controlling autophagy could be beneficial in the development of more effective chemotherapies against leukemia.
基金:
Grant-in-
Aid for Scientific Research (B) (No. 24390159) from the Japan
Society for the Promotion of Science to Y. Yoshida.
第一作者机构:[1]Univ Occupat & Environm Hlth, Dept Immunol & Parasitol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan
通讯作者:
推荐引用方式(GB/T 7714):
Nakanishi Tsukasa,Song Yuan,He Cuiying,et al.Autophagy is associated with cucurbitacin D-induced apoptosis in human T cell leukemia cells[J].MEDICAL ONCOLOGY.2016,33(4):doi:10.1007/s12032-016-0743-y.
APA:
Nakanishi, Tsukasa,Song, Yuan,He, Cuiying,Wang, Duo,Morita, Kentaro...&Yoshida, Yasuhiro.(2016).Autophagy is associated with cucurbitacin D-induced apoptosis in human T cell leukemia cells.MEDICAL ONCOLOGY,33,(4)
MLA:
Nakanishi, Tsukasa,et al."Autophagy is associated with cucurbitacin D-induced apoptosis in human T cell leukemia cells".MEDICAL ONCOLOGY 33..4(2016)